« Back to Record
Citation APA

Gonzalez-Ericsson, P. I., Stovgaard, E. E., Sua, L. F., Reisenbichler, E., Kos, Z., Carter, J. M., Michiels, S., Le Quesne, J., Nielsen, T. O., Laenkholm, A.-V., Fox, S. B., Adam, J., Bartlett, J. M. S., Rimm, D. L., Quinn, C., Peeters, D., Dieci, M. V., Vincent-Salomon, A., Cree, I., Hida, A. I., Balko, J. M., Haynes, H. H., Frahm, I., Acosta-Haab, G., Balancin, M. L., Bellolio, E., Yang, W., Kirtani, P., Sugie, T., Ehinger, A., Castaneda, C. A., Kok, M., McArthur, H., Siziopikou, K., Badve, S., Fineberg, S., Gown, A. A., Viale, G., Schnitt, S. J., Pruneri, G., Penault-Llorca, F., Hewitt, S. M., Thompson, E. A., Allison, K. H., Symmans, W. F., Bellizzi, A. M., Brogi, E., Moore, D. A., Larsimont, D., Dillon, D. A., Lazar, A., Lien, H., Goetz, M. P., Broeckx, G., El Bairi, K., Harbeck, N., Cimino-Mathews, A., Sotiriou, C., Adams, S., Liu, S.-W., Loibl, S., Chen, I.-C., Lakhani, S. R., Juco, J. W., Denkert, C., Blackley, E. E., Demaria, S., Leon-Ferre, R., Gluz, O., Zardavas, D., Emancipator, K., Ely, S., Loi, S., Salgado, R., Sanders, M. M., & International Immuno-Oncology Biomarker Working Group, (2020). The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice. Journal of pathology. doi:10.1002/path.5406


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/303137

Gonzalez-Ericsson, P. I., Stovgaard, E. E., Sua, L. F., Reisenbichler, E., Kos, Z., Carter, J. M., Michiels, S., Le Quesne, J., Nielsen, T. O., Laenkholm, A.-V., Fox, S. B., Adam, J., Bartlett, J. M. S., Rimm, D. L., Quinn, C., Peeters, D., Dieci, M. V., Vincent-Salomon, A., Cree, I., Hida, A. I., Balko, J. M., Haynes, H. H., Frahm, I., Acosta-Haab, G., Balancin, M. L., Bellolio, E., Yang, W., Kirtani, P., Sugie, T., Ehinger, A., Castaneda, C. A., Kok, M., McArthur, H., Siziopikou, K., Badve, S., Fineberg, S., Gown, A. A., Viale, G., Schnitt, S. J., Pruneri, G., Penault-Llorca, F., Hewitt, S. M., Thompson, E. A., Allison, K. H., Symmans, W. F., Bellizzi, A. M., Brogi, E., Moore, D. A., Larsimont, D., Dillon, D. A., Lazar, A., Lien, H., Goetz, M. P., Broeckx, G., El Bairi, K., Harbeck, N., Cimino-Mathews, A., Sotiriou, C., Adams, S., Liu, S.-W., Loibl, S., Chen, I.-C., Lakhani, S. R., Juco, J. W., Denkert, C., Blackley, E. E., Demaria, S., Leon-Ferre, R., Gluz, O., Zardavas, D., Emancipator, K., Ely, S., Loi, S., Salgado, R., Sanders, M. M., & International Immuno-Oncology Biomarker Working Group, (2020). The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice. Journal of pathology. doi:10.1002/path.5406